Chapter 14. Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases

  1. Stephen D. Wiviott MD Assistant Professor Investigator
  1. Larry B. Goldstein MD, FAAN, FAHA

Published Online: 19 FEB 2009

DOI: 10.1002/9781444303339.ch14

Antiplatelet Therapy In Ischemic Heart Disease

Antiplatelet Therapy In Ischemic Heart Disease

How to Cite

Goldstein, L. B. (2008) Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases, in Antiplatelet Therapy In Ischemic Heart Disease (ed S. D. Wiviott), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303339.ch14

Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

Author Information

  1. Department of Medicine (Neurology), Center for Cerebrovascular Disease, Center for Clinical Health Policy Research, Duke University and Durham VA Medical Center, Durham, NC, USA

Publication History

  1. Published Online: 19 FEB 2009
  2. Published Print: 28 NOV 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman MD, FAHA

Series Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

ISBN Information

Print ISBN: 9781405176262

Online ISBN: 9781444303339

SEARCH

Keywords:

  • platelet antiaggregant drugs;
  • antiplatelet agents for prevention of recurrent ischemic stroke;
  • Ticlopidine Aspirin Stroke Study (TASS);
  • Trifusal versus Aspirin in Cerebral Infarction Prevention (TACIP) trial;
  • secondary prevention with antiplatelet agents versus warfarin;
  • antiplatelet agents in acute ischemic stroke;
  • platelet antiaggregants associated with reduced risk of stroke and vascular events

Summary

This chapter contains sections titled:

  • Antiplatelet agents for the primary prevention of ischemic stroke

  • Antiplatelet agents for prevention of recurrent ischemic stroke

  • Secondary prevention with antiplatelet agents versus warfarin in specific conditions

  • Antiplatelet agents in acute ischemic stroke

  • Summary

  • References